Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 118 of 118

TitleReference numberPublishedLast updated
Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessmentHTE18
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)TA969
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA968
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)TA966
Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedemaIPG785
Endometriosis: diagnosis and managementNG73
Cabozantinib with nivolumab for untreated advanced renal cell carcinomaTA964
Twin and triplet pregnancyNG137
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA963
Kurin Lock for blood culture collectionMTG77
GaitSmart rehabilitation exercise programme for gait and mobility issuesMTG78
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancerIPG784
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)TA961
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapyTA962
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)TA965
Ritlecitinib for treating severe alopecia areata in people 12 years and overTA958
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosisTA959
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)TA960
Desflurane for maintenance of anaesthesiaES41
Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessmentHTE17
Ovarian cancer: identifying and managing familial and genetic riskNG241
Momelotinib for treating myelofibrosis-related splenomegaly or symptomsTA957
Suspected sepsis: recognition, diagnosis and early managementNG51
Neonatal infection: antibiotics for prevention and treatmentNG195
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and managementNG240
ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessmentHTE5
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19TA878
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedemaTA953
Dupilumab for treating moderate to severe prurigo nodularisTA955
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and overTA956
Lung cancer: diagnosis and managementNG122
Vitamin B12 deficiency in over 16s: diagnosis and managementNG239
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA954
Digital technologies for delivering multidisciplinary weight-management services: early value assessmentHTE14
Digital technologies for managing non-specific low back pain: early value assessmentHTE16
Endoscopic sleeve gastroplasty for obesityIPG783
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutationsTA952
TuberculosisNG33
Digitally enabled therapies for adults with depression: early value assessmentHTE8
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and overTA949
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and overTA950
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancerTA951
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatmentsTA947
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatmentsTA948
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)TA945
Caesarean birthNG192
Devices for remote monitoring of Parkinson's diseaseDG51
COVID-19 rapid guideline: managing the long-term effects of COVID-19NG188
Skin cancerQS130
Pharyngeal electrical stimulation for neurogenic dysphagiaIPG781
Temperature control to improve neurological outcomes after cardiac arrestIPG782
Neonatal infectionQS75
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancerTA946
Early and locally advanced breast cancer: diagnosis and managementNG101
Sebelipase alfa for treating Wolman diseaseHST30
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Intravascular lithotripsy for calcified arteries in peripheral arterial diseaseIPG780
Bipolar disorder: assessment and managementCG185
Epilepsies in children, young people and adultsQS211
Targeted-release budesonide for treating primary IgA nephropathyTA937
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)TA940
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)TA941
Empagliflozin for treating chronic kidney diseaseTA942
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetesTA943
Risdiplam for treating spinal muscular atrophyTA755
Digitally enabled therapies for adults with anxiety disorders: early value assessmentHTE9
Middle meningeal artery embolisation for chronic subdural haematomasIPG779
Cardiovascular disease: risk assessment and reduction, including lipid modificationNG238
Transition from children's to adults' servicesQS140
Velmanase alfa for treating alpha-mannosidosisHST29
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Acne vulgaris: managementNG198
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)TA938
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936
Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolismIPG778
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)TA933
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptomsTA934
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)TA932
Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosisIPG777
Zanubrutinib for treating chronic lymphocytic leukaemiaTA931
Transient loss of consciousness ('blackouts') in over 16sCG109
Hypertension in adults: diagnosis and managementNG136
Suspected acute respiratory infection in over 16s: assessment at first presentation and initial managementNG237
Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessmentHTE15
Biodegradable subacromial spacer insertion for rotator cuff tearsIPG775
Extracorporeal carbon dioxide removal for acute respiratory failureIPG776
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatmentsTA930
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancerCG164
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fractionTA929
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodineTA928
Jaundice in newborn babies under 28 daysCG98
Pneumonia in adults: diagnosis and managementCG191
Acute respiratory infection in over 16s: initial assessment and management including virtual wards (hospital at home)QS210
Ranibizumab for treating diabetic macular oedemaTA274
Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditionsIPG774
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableTA917
Tirzepatide for treating type 2 diabetesTA924
Mirikizumab for treating moderately to severely active ulcerative colitisTA925
Baricitinib for treating severe alopecia areataTA926
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)TA923
Percutaneous deep venous arterialisation for chronic limb-threatening ischaemiaIPG773
Stroke rehabilitation in adultsNG236
Rimegepant for treating migraineTA919
Tofacitinib for treating active ankylosing spondylitisTA920
Ruxolitinib for treating polycythaemia veraTA921
Daridorexant for treating long-term insomniaTA922
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA927
Virtual ward platform technologies for acute respiratory infectionsHTE13
Thyroid disease: assessment and managementNG145
Bimekizumab for treating axial spondyloarthritisTA918
Pegunigalsidase alfa for treating Fabry diseaseTA915
Bimekizumab for treating active psoriatic arthritisTA916
Urinary incontinence in neurological disease: assessment and managementCG148
Ovarian cancer: recognition and initial managementCG122
Suspected cancer: recognition and referralNG12
Suspected neurological conditions: recognition and referralNG127
Hearing loss in adults: assessment and managementNG98

Results per page

  1. 10
  2. 25
  3. 50
  4. All